Best Biologics / mAb CDMOs in Switzerland

Scale & bioreactor fit

Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.

Cell line & process development

Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.

Regulatory track record

Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.

Drug substance to drug product

Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.

The Swiss CDMO cluster (Basel, Visp, Bern) hosts three attributes that reinforce a premium tier positioning: (1) regulatory alignment — Switzerland's Swissmedic runs a mutual-recognition GMP framework with the EU, so a Swiss facility supplying the EU doesn't need parallel EMA certification for the same activities; (2) technical depth — Swiss CDMOs have historically led on complex chemistry (Lonza on biologics + peptides, Bachem on peptides, CordenPharma on APIs) and on early-adopter viral vector manufacturing; (3) capital access — Swiss operations are able to make sustained capex investments in single-site scale-ups that lower-cost jurisdictions cannot match. That said, Swiss CDMOs also carry higher per-batch costs than Asian or Eastern European alternatives — the trade-off is process depth and regulatory posture, not price.

Switzerland is not an EU member state but maintains a bilateral Mutual Recognition Agreement (MRA) with the EU covering GMP inspections. Practically: a Swissmedic GMP inspection is recognized by EMA as equivalent to an EMA GMP inspection for the covered activity. Swiss-manufactured product does still require an EU-based Qualified Person for batch release into the EU market, but the facility itself does not need parallel EMA certification. This makes Swiss CDMOs operationally cleaner for pan-European supply than most non-EU alternatives. For UK supply, post-Brexit MHRA has continued to recognize the Swissmedic MRA under transitional arrangements — sponsors supplying both EU and UK should confirm current MHRA policy at RFP stage.

The largest Swiss CDMOs — Lonza, CordenPharma, Bachem — operate global site networks spanning Switzerland, US, and (in Lonza's case) multiple Asian geographies. This multi-region posture materially reduces regulatory tech-transfer risk for programs supplying multiple markets from a single CDMO relationship. Cross-check with the US region ranking and Asia region ranking to identify Swiss-headquartered CDMOs with cross-jurisdictional footprint. Individual profile pages surface the specific site network.

What should I look for in a biologics CDMO?

Match bioreactor scale and modality (mAb, bispecific, fusion protein) to your program, confirm cell-line and process-development support, and prioritize a clean FDA and EMA/MHRA record at the scale you'll commercialize at.

What is the difference between a biologics CDMO and a cell or gene therapy CDMO?

Biologics CDMOs make large molecules (antibodies, proteins) in bioreactors at litre-to-thousands-of-litre scale. Cell and gene therapy CDMOs make living cells or viral vectors in much smaller, often per-patient batches under different containment and analytics.